Oxford University to Study Adalimumab as Potential COVID-19 Treatment

LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: DMARDs & Immunosuppressives Drug Updates adalimumab COVID-19 Source Type: research